Investigation of Macrophage Polarization in Peri-implant Health and Peri-implantitis
Peri-implantitis is a chronic inflammatory disease characterized by plaque-associated inflammation of the peri-implant mucosa and progressive loss of supporting bone around dental implants, which may ultimately lead to implant failure if left untreated.
It has been demonstrated that cellular and molecular responses of the host immune defense system play a critical role in the pathogenesis of peri-implantitis. Macrophages are key cells in the host immune response and are generally classified into two phenotypes: pro-inflammatory (M1) and anti-inflammatory (M2). While M1 macrophages are actively involved in the early defense response, a shift toward the M2 phenotype is required for the resolution of inflammation and tissue repair.
Smoking has been shown to adversely affect macrophage polarization and function, thereby exacerbating inflammatory responses. Therefore, in the present study, levels of soluable CD163 (sCD163), B cell activating factor (BAFF), tumor necrosis factor-like weak inducer of apoptosis (TWEAK), a proliferation-inducing ligand (APRIL), interferon-gamma (IFN-γ), interleukin-10 (IL-10), interleukin-34 (IL-34), interleukin-35 (IL-35), and arginase activity (ornithine levels) will be evaluated in peri-implant health and peri-implantitis patients with varying disease severity and different smoking statuses. In addition, a comprehensive proteomic analysis will be performed to investigate the relationships among peri-implantitis severity, smoking, and macrophage polarization-related molecules. Baseline periodontal and peri-implant parameters will be recorded for all participants. In the peri-implant health group, tissue samples will be collected during exposure surgery performed for submerged implants, after which participants will be enrolled in supportive peri-implant care. Participants diagnosed with peri-implantitis will receive non-surgical therapy, during which tissue samples will be collected. Periodontal and peri-implant parameters will be reassessed for all participants at baseline, and at 6 and 12 weeks. Healthy peri-implant samples will be collected from submerged implants during exposure surgery. Peri-implantitis samples (probable pocket depth ≥ 6 mm with bleeding on probing) will be obtained during non-surgical therapy using a single stroke along the pocket wall.
Přehled studie
Postavení
Podmínky
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní místa
-
-
-
Istanbul, Turecko (Türkiye)
- Nábor
- Biruni University
-
Kontakt:
- Burcu Karaduman
- Telefonní číslo: +905323763366
- E-mail: bkaraduman@biruni.edu.tr
-
Dílčí vyšetřovatel:
- Ayse Kaban
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- Individuals who is suitable for the peri-implantitis diagnosis according to the classifications of periodontal and peri-implant diseases and conditions established in 2017.
- Individuals with at least one bone-level dental implant and scheduled to undergo exposure surgery.
Exclusion Criteria:
- prior peri-implantitis surgery
- being diagnosed with autoimmune disease, genetic disorders, bone metabolism disorders, poorly controlled systemic diseases (such as diabetes or hypertension)
- pregnancy or lactation
- having a history of oral malignancy, chemotherapy or radiotherapy
- use of anti-inflammatory drugs within 2 weeks, antibiotics within 3 months,
- need for prophylactic antibiotics
- contraindications for dental/surgical procedures.
Studijní plán
Jak je studie koncipována?
Detaily designu
Kohorty a intervence
Skupina / kohorta |
|---|
|
Peri-implant health - smokers
Individuals with at least one bone-level dental implant, who are current smokers, and are scheduled to undergo exposure surgery.
|
|
Peri-implant health - non-smokers
Individuals with at least one bone-level dental implant, who are non-smokers, and are scheduled to undergo exposure surgery.
|
|
Peri-implantitis - non-smokers
Individuals with peri-implantitis (non-smokers) were defined as subjects who were non-smokers and presented with bleeding and/or suppuration on gentle probing, an increased probing depth compared to previous examinations, and radiographic evidence of bone loss beyond crestal bone level changes resulting from initial bone remodelling.
In cases where previous examination data were not available, peri-implantitis was diagnosed based on the presence of bleeding and/or suppuration on gentle probing, probing depths of ≥6 mm, and radiographic bone levels ≥3 mm apical to the most coronal portion of the intraosseous part of the implant.
|
|
Peri-implantitis - smokers
Individuals with peri-implantitis (smokers) were defined as subjects who were current smokers and presented with bleeding and/or suppuration on gentle probing, an increased probing depth compared to previous examinations, and radiographic evidence of bone loss beyond crestal bone level changes resulting from initial bone remodelling.
In cases where previous examination data were not available, peri-implantitis was diagnosed based on the presence of bleeding and/or suppuration on gentle probing, probing depths of ≥6 mm, and radiographic bone levels ≥3 mm apical to the most coronal portion of the intraosseous part of the implant.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Evaluation of soluable CD163 (sCD163) levels
Časové okno: Baseline
|
sCD163 levels in tissue samples collected from the participants will be evaluated using Bio-Plex multiplex kits.
The results of the biochemical analyses will be reported as pg/ng.
|
Baseline
|
|
Evaluation of a proliferation-inducing ligand (APRIL) levels
Časové okno: Baseline
|
APRIL levels in tissue samples collected from the participants will be evaluated using Bio-Plex multiplex kits.
The results of the biochemical analyses will be reported as pg/ng.
|
Baseline
|
|
Evaluation of B-cell activating factor (BAFF) levels
Časové okno: Baseline
|
BAFF levels in tissue samples collected from the participants will be evaluated using Bio-Plex multiplex kits.
The results of the biochemical analyses will be reported as pg/ng.
|
Baseline
|
|
Evaluation of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) levels
Časové okno: Baseline
|
TWEAK levels in tissue samples collected from the participants will be evaluated using Bio-Plex multiplex kits.
The results of the biochemical analyses will be reported as pg/ng.
|
Baseline
|
|
Evaluotion of interleukin-10 (IL-10) levels
Časové okno: Baseline
|
IL-10 levels in tissue samples collected from the participants will be evaluated using Bio-Plex multiplex kits.
The results of the biochemical analyses will be reported as pg/ng.
|
Baseline
|
|
Evaluation of interleukin-34 (IL-34) Levels
Časové okno: Baseline
|
IL-34 levels in tissue samples collected from the participants will be evaluated using Bio-Plex multiplex kits.
The results of the biochemical analyses will be reported as pg/ng.
|
Baseline
|
|
Evaluation of interleukin-35 (IL-35) levels
Časové okno: Baseline
|
IL-35 levels in tissue samples collected from the participants will be evaluated using Bio-Plex multiplex kits.
The results of the biochemical analyses will be reported as pg/ng.
|
Baseline
|
|
Evaluation of arginase activity
Časové okno: Baseline
|
Arginase activity in tissue samples collected from the participants will be evaluated using Chinard's method by determined ornithine levels.
The results of the biochemical analyses will be reported as pg/ng.
|
Baseline
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Probable pocket depth (PPD)
Časové okno: Baseline and 6th week.
|
Probable pocket depth wiil be measured using a periodontal probe
|
Baseline and 6th week.
|
|
Bleeding on probing (BoP)
Časové okno: Baseline and 6th week.
|
The presence of visible bleeding following periodontal probing will be assessed by visual inspection (+/-).
The total bleeding score will be expressed as a percentage.
|
Baseline and 6th week.
|
|
Plaque index
Časové okno: Baseline and 6th week.
|
The presence of visible plaque will be evaluated with a periodontal probe (+/-).
The total plaque score will be expressed as a percentage.
|
Baseline and 6th week.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Studijní židle: Burcu Karaduman, PhD, Biruni University
- Studijní židle: Ulvi K Gursoy, PhD, University of Turku
- Studijní židle: Mustafa Yilmaz, PhD, Istanbul University
- Vrchní vyšetřovatel: Ayse Kaban, Biruni University
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 2024-BIAEK/16-60
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Peri-implantitida
-
Nantes University HospitalDokončenoPrimární Raynaudův fenomén (PR) | Genetické mutace způsobující PR | Studie pacientů a jejich příbuzných (s nebo bez primární PR)Francie
-
Ain Shams UniversityDokončenoHodnocení PR fixace u zranění dlaždic B2 a C1Egypt
-
Gruppo Italiano Malattie EMatologiche dell'AdultoDokončenoPacienti s relapsem CLL po počáteční odpovědi (CR, PR ≥ 6 měsíců) po ne více než dvou předchozích léčebných liniích; nebo | Pacienti s CLL refrakterní (SD, PD nebo CR/PR < 6 měsíců) po ne více než dvou předchozích léčebných liniíchItálie
-
Peregrine PharmaceuticalsStaženoRakovina prsu | Triple negativní rakovina prsu | Trojité negativní novotvary prsu | Triple-negativní rakovina prsu | Triple-negativní novotvar prsu | ER-negativní PR-negativní HER2-negativní novotvary prsu | ER-negativní PR-negativní HER2-negativní rakovina prsu
-
PfizerDokončenoKlinický výsledek hormonálního receptoru pozitivního, HER-2 negativního karcinomu prsu na Tchaj-wanuER/PR (+), HER2 (-) Rakovina prsuTchaj-wan
-
Dana-Farber Cancer InstituteBreast Cancer Research FoundationZatím nenabírámeRakovina prsu | Karcinom prsu | ER pozitivní rakovina prsu | Rakovina prsu – žena | PR-pozitivní rakovina prsuSpojené státy
-
OncoSec Medical IncorporatedDokončenoER-negativní PR-negativní HER2-negativní rakovina prsuSpojené státy
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI); Syndax PharmaceuticalsUkončenoRakovina prsu | Invazivní rakovina prsu | ER-negativní PR-negativní HER2-negativní rakovina prsuSpojené státy
-
Ruth O'ReganUniversity of Rochester; Puma Biotechnology, Inc.NáborRakovina prsu | HER2-pozitivní rakovina prsu | ER pozitivní rakovina prsu | PR-pozitivní rakovina prsuSpojené státy